$88.14
Medtronic PLC (MDT) is a leading medical devices business with stocks listed in the US. It opened the day at US$89.02 after a previous close of US$89.12. During the day the price has varied from a low of USD87.94 to a high of USD89.2365. The latest price was USD88.135 (25 minute delay). Medtronic is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Medtronic
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Medtronic. Find the share by name or ticker symbol: MDT. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Medtronic reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$89.12, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Medtronic, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Medtronic. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Our top pick for
US stocks
Our top pick for
Copy trading
Our top pick for
Mobile app
Medtronic stock price (NYSE:MDT)
Use our graph to track the performance of MDT stocks over time.Have Medtronic's shares ever split?
Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
Medtronic shares at a glance
Open | US$89.02 |
---|---|
High | US$89.2365 |
Low | US$87.94 |
Close | US$88.135 |
Previous close | US$89.12 |
Change | US$-0.985 |
Change % | -1.1053% |
Volume | 797,900 |
52-week range | US$66.585 - US$90.774 |
---|---|
50-day moving average | US$85.6038 |
200-day moving average | US$83.6605 |
Target price | US$94.34 |
PE ratio | 30.0741 |
Dividend yield | US$2.77 (3.13%) |
Earnings per share (TTM) | US$2.97 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Medtronic price performance over time
Historical closes compared with the last close of $88.135
1 week (2024-09-26) | -1.47% |
---|---|
1 month (2024-09-03) | -0.93% |
3 months (2024-07-03) | 14.21% |
6 months (2024-04-03) | 3.69% |
1 year (2023-10-03) | 15.15% |
---|---|
2 years (2022-10-03) | 6.57% |
3 years (2021-10-01) | -30.77% |
5 years (2019-10-03) | -17.58% |
Compare trading platforms to buy Medtronic shares
Is it a good time to buy Medtronic stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Medtronic under- or over-valued?
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's P/E ratio
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Medtronic shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Medtronic's PEG ratio
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6544. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9 billion (£6.9 billion).
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure stock profitability.
Medtronic share price volatility
Over the last 12 months, Medtronic's shares have ranged in value from as little as US$66.585 up to US$90.774. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.854. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
N/AMedtronic financials
Revenue TTM | US$32.6 billion |
---|---|
Operating margin TTM | 17.51% |
Gross profit TTM | US$21.7 billion |
Return on assets TTM | 4.42% |
Return on equity TTM | 7.95% |
Profit margin | 12.06% |
Book value | 37.386 |
Market capitalisation | US$114.6 billion |
EBITDA | US$9 billion |
TTM: trailing 12 months
Medtronic share dividends
Dividend payout ratio: 53.05% of net profits
Recently Medtronic has paid out, on average, around 53.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.13% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.13% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.77 per share.
Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Medtronic's most recent dividend payout was on 10 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 26 September 2024 (the "ex-dividend date").
Medtronic's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Medtronic's total ESG risk score
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Medtronic's environmental score
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Medtronic's social score
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Medtronic's governance score
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Medtronic's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Medtronic PLC was last rated for ESG on: 2019-01-01.
Total ESG score | 26.86 |
---|---|
Total ESG percentile | 40.62 |
Environmental score | 4.07 |
Environmental score percentile | 5 |
Social score | 15.28 |
Social score percentile | 5 |
Governance score | 9 |
Governance score percentile | 5 |
Level of controversy | 3 |
Medtronic overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
Medtronic in the news
3 Stocks to Buy if the Fed Keeps Rates High for the Rest of 2024
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
Activist Daniel Loeb Seeks to Repair Advance Auto Parts
Frequently asked questions
More guides on Finder
-
Syfe review
Syfe is an all-in-one platform that allows you to buy and sell crypto and shares from one app. Here is what you need to know about the product.
-
Ethical investing in Australia
Ethical investing is predicted to surge in 2024. Here is what you need to know to be part of this growing trend.
-
How to start a share portfolio in Australia
There are 3 main options available to you in Australia if you want to build a portfolio of company stocks
-
Sharesies review
Here's a detailed review of micro-investing app Sharesies plus its key features and pros and cons.
-
Pearler review
Is online broker Pearler the right choice for you? Find out in this guide to Pearler’s fees and features.
-
CommSec vs Selfwealth
We rate the fees and features of both online brokers.
-
moomoo Australia review
Gain access to the US and Australian markets for less through moomoo share trading accounts.
-
Stake review: A trading platform for AU and US stocks
Stake is a trading platform for Australians who want value for money when trading. Gain access to the cheapest CHESS-sponsored brokerage in Australia and $3 brokerage in the US.
-
Westpac Share Trading Account review
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.
-
What is a managed fund?
What are managed funds? Read our guide and learn the different types of managed funds available.
Ask a question